Category Archives: Seth Klarman

Seth Klarman And Kindred Biosciences (KIN)

On January 10, 2014 Seth Klarman (Baupost Group) acquired 2.9 million shares of Kindred Biosciences at an average cost of $11.17 per share.  This represents 17.93% of all the outstanding shares of the company.  Kindred is a development stage company developing pharmaceuticals for the pet industry.  Its flagship product is a drug called CereKin, a beef flavored dog … Continue reading